

Approved Professional Information for Medicines for Human Use:

MEROPENEM 500 SHANUR AND MEROPENEM 1000 SHANUR

SCHEDULING STATUS

S4

1. NAME OF THE MEDICINE

MEROPENEM 500 SHANUR (Powder for solution for injection or infusion)

MEROPENEM 1000 SHANUR (Powder for solution for injection or infusion)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

MEROPENEM 500 SHANUR

Each vial contains meropenem (as trihydrate) 570 mg, equivalent to 500 mg anhydrous meropenem.

MEROPENEM 1000 SHANUR

Each vial contains meropenem (as trihydrate) 1140 mg, equivalent to 1000 mg anhydrous meropenem.

Sugar free.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Powder for solution for injection or infusion

Powder:

Clear glass vial containing a white to light yellow powder.

Reconstituted solution:

The solution is clear and varies from colourless to yellow depending on the concentration. The solution is free of any visible particles.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

MEROPENEM SHANUR is indicated for treatment of the following infections, caused by single or multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms:

Acute exacerbation of chronic bronchitis and pneumonia due to:

Staphylococcus aureus (methicillin-susceptible strains only), *Streptococcus pneumoniae*, *Streptococcus* spp., *Escherichia coli*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Pseudomonas aeruginosa*, *Moraxella (Branhamella) catarrhalis*, *Klebsiella* spp., *Enterobacter cloacae*, *Enterobacter* spp., *Acinetobacter* spp.

Pneumonia in children due to:

Staphylococcus aureus (methicillin-susceptible strains only), *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Pseudomonas aeruginosa*.

Urinary tract infections in adults and children, including complicating infections due to:

Enterobacter cloacae, *Escherichia coli*, *Morganella morganii*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Serratia marcescens*, *Citrobacter freundii*.

Pelvic Inflammatory Disease (including tubo-ovarian abscess) and endometritis due to:

Enterococcus faecalis, *Staphylococcus aureus* (methicillin-susceptible strains only) coagulase-negative *Staphylococcus* spp. (methicillin-susceptible strains only), *Streptococcus agalactiae* (Group B), *Streptococcus viridans*, *Streptococcus* spp., *Escherichia coli*, *Neisseria gonorrhoeae*, *Klebsiella pneumoniae*, *Enterobacter aerogenes*, *Enterobacter cloacae*, *Proteas mirabilis*, *Acinetobacter anitratus*, *Acinetobacter lwoffii*, *Gardnerella vaginalis*, *Bacteroides fragilis* group, *Peptostreptococcus anaerobius*, *Peptostreptococcus asaccharolyticus*, *Peptostreptococcus magnus*.

Skin and skin structure infections in adults due to:

Staphylococcus aureus (methicillin-susceptible strains only), coagulase-negative *Staphylococcus* spp. (methicillin-susceptible strains only), *Streptococcus pyogenes* (Group A), *Streptococcus agalactiae*, *Streptococcus viridans*, *Enterococcus faecalis*, *Escherichia coli*,

Dezzo Trading 392 (Pty) Ltd, 580034-5, MEROPENEM 500 SHANUR, MEROPENEM 1000 SHANUR, Powder for solution for injection or infusion, 500 mg & 1000 mg

Klebsiella pneumoniae, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Bacteroides fragilis*,
Peptostreptococcus spp.

Meningitis in adults and children due to:

Streptococcus pneumoniae, *Haemophilus influenzae*, *Neisseria meningitidis*.

Septicaemia in adults and children due to:

Streptococcus pneumoniae, *Escherichia coli*, *Klebsiella pneumoniae*.

Empiric treatment, including initial monotherapy, for presumed bacterial infections in host-compromised neutropenic patients due to:

Streptococcus epidermidis, *Streptococcus mitis*, *Streptococcus sanguinis*, *Escherichia coli*.

Intra-abdominal abscess and peritonitis due to:

Streptococcus milleri, *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Pseudomonas aeruginosa*, *Bacteroides fragilis* group (including *Bacteroides distasonis*, *Bacteroides fragilis*, *Bacteroides ovatus*, *Bacteroides thetaiotaomicron*, *Bacteroides vulgatus*), *Clostridium perfringens*, *Streptococcus mitior*.

Polymicrobial infections

4.2 Posology and method of administration

Posology

Intravenous administration:

Adults:

Usual dose:

500 mg to 1 g by intravenous administration every 8 hours depending on the type and severity of infection, the known or suspected susceptibility of the pathogen(s), and the condition of the patient.

See section 4.1 for types of infections and *in vivo* susceptible organisms.

Exceptions:

(1) Febrile episodes in neutropenic patients- the dose should be 1 g every 8 hours.

(2) Meningitis – the dose should be 2 g every 8 hours.

Caution may be required in using beta-lactam antibiotics in critically ill patients with known or suspected *Pseudomonas aeruginosa* lower respiratory tract infections.

Concomitant use of an aminoglycoside is recommended.

Regular sensitivity testing is recommended when treating *Pseudomonas aeruginosa*.

MEROPENEM SHANUR should be given as an intravenous bolus injection over approximately 5 minutes or by intravenous infusion over approximately 15 - 30 minutes.

(see Constitution, compatibility, and stability section for constitution details).

Dosage schedule for adults with impaired renal function:

Dosage should be reduced in patients with creatinine clearance less than 51 mL/minute, as scheduled below.

Creatinine clearance (mL/min)	Dose (based on “unit” dose range of 500 mg to 2 g every 8 hours – see above)	Frequency
26 - 50	One unit dose	Every 12 hours
10 - 25	One-half unit dose	Every 12 hours
< 10	One-half unit dose	Every 24 hours

MEROPENEM SHANUR is cleared by haemodialysis, if continued treatment with MEROPENEM SHANUR is necessary, the unit dose is based on the infection type and severity is recommended at the completion of the haemodialysis procedure to re-institute effective treatment.

There is no experience with peritoneal dialysis.

Use in adults with hepatic insufficiency:

No dosage adjustment is necessary in patients with impaired hepatic metabolism.

Elderly:

No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 mL/minute.

Children:

For infants and children over 3 months and up to 12 years of age the IV dose is 10 – 40 mg/kg every 8 hours depending on type and severity of infection, the known or suspected susceptibility of the pathogen(s), and the condition of the patient. In children over 50 kg weight, adult dosage should be used.

Exceptions:

Meningitis – the dose should be 40 mg/kg every 8 hours.

MEROPENEM SHANUR should be given as an IV bolus over approximately 5 minutes or by intravenous infusion over approximately 15 – 30 minutes (see Constitution, compatibility and stability section for details).

There is no experience in children with renal impairment.

Method of Administration

For intravenous use only.

4.3 Contraindications

- Hypersensitivity to meropenem or to any of the excipients listed in section 6.1.
- Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics, may also be hypersensitive to MEROPENEM SHANUR.

4.4 Special warnings and precautions for use

Prescribers should adhere to the principles of antibiotic stewardship.

The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial medicine (such as meropenem) based on factors such as severity of the infection, prevalence of resistance to other suitable antibacterial medicines and the risk of selecting for carbapenem-resistant bacteria.

Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. Resistance

Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. resistance to penems such as meropenem has been reported. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.

Paediatric use

Efficacy and tolerability in infants under 3 months old have not been established, therefore, MEROPENEM SHANUR is not recommended for use below this age.

Hypersensitivity reactions

Serious and occasionally fatal hypersensitivity reactions have been reported with meropenem. Before initiating therapy with MEROPENEM SHANUR, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics. If a severe allergic reaction occurs with MEROPENEM SHANUR treatment, it should be discontinued, and appropriate measures taken. Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem (see section 4.8). If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.

Antibiotic-associated colitis

Overgrowth of non-susceptible organisms may occur, and repeated evaluation of each patient is necessary. Pseudomembranous colitis has been reported with MEROPENEM SHANUR, therefore, it is important to consider its diagnosis in patients who develop diarrhoea in association with MEROPENEM SHANUR use. Medicines that inhibit peristalsis should not be given.

Seizures

Seizures have been reported during treatment with meropenem, such as MEROPENEM SHANUR.

Use in patients with liver disease

Patients with pre-existing liver disorders must have liver function monitored during treatment with

Dezzo Trading 392 (Pty) Ltd, 580034-5, MEROPENEM 500 SHANUR, MEROPENEM 1000 SHANUR, Powder for solution for injection or infusion, 500 mg & 1000 mg

MEROPENEM SHANUR, due to the risk of hepatotoxicity such as cholestasis and cytolysis.

Direct antiglobulin test seroconversion

A positive direct or indirect antiglobulin test may develop.

Concomitant use with valproic acid/sodium valproate/valpromide

The concomitant use of meropenem and valproic acid/sodium valproate/valpromide is not recommended (see section 4.5).

Excipients of MEROPENEM SHANUR

MEROPENEM SHANUR contains sodium, and this should be taken into consideration by patients on a controlled sodium diet.

4.5 Interaction with other medicines and other forms of interaction

MEROPENEM SHANUR may reduce serum valproic acid levels. Subtherapeutic levels may be reached in some patients.

Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. As the potency and duration of action of MEROPENEM SHANUR dosed without probenecid are adequate the co-administration of probenecid with MEROPENEM SHANUR is not recommended.

The potential effect of MEROPENEM SHANUR on the protein binding of other medicines or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected.

MEROPENEM SHANUR has been administered concomitantly with many other medicines without apparent adverse interaction.

However, no specific data regarding other interactions are available.

Oral anti-coagulants

Simultaneous administration of MEROPENEM SHANUR with warfarin may augment its anti-coagulant effects. There have been many reports of increases in the anti-coagulant

effects of orally administered anticoagulant medicines, including warfarin in patients who are concomitantly receiving antibacterial medicines. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalized ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after coadministration of antibiotics with an oral anticoagulant medicine.

4.6 Fertility, pregnancy and lactation

Pregnancy

The safety of MEROPENEM SHANUR in human pregnancy has not been established.

MEROPENEM SHANUR should not be given to pregnant women.

Breastfeeding

Meropenem is detectable at very low concentrations in animal breast milk.

MEROPENEM SHANUR should not be used in breastfeeding women.

Fertility

No data on fertility available.

4.7 Effects on ability to drive and use machines

No studies on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesia and convulsions have been reported for meropenem.

4.8 Undesirable effects

a) Tabulated list of adverse reactions

The table below shows all adverse drug reactions (ADRs) observed during clinical trials and postmarket spontaneous reports with meropenem.

System Organ Class	Frequency		
	Frequent	Less Frequent	Not known
Infections and infestations		Oral and vaginal candidiasis	
Blood and lymphatic system disorders	Thrombocythaemia	Eosinophilia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis, haemolytic anaemia	
Immune system disorders		Angioedema, anaphylaxis	
Psychiatric disorders		Delirium	
Nervous system disorders	Headache	Paraesthesia, convulsions	
Gastrointestinal disorders	Nausea, vomiting, diarrhoea, abdominal pain	Antibiotic-associated colitis	

Hepatobiliary disorders	Increases in serum transaminases, alkaline phosphatase, lactate dehydrogenase	Increased blood bilirubin	
Skin and subcutaneous tissue disorders	Rash, pruritus	Urticaria, erythema multiforme, Stevens Johnson Syndrome, Toxic Epidermal Necrolysis	Drug reactions with eosinophilia and systemic symptoms (DRESS), generalised exanthematous pustulosis
Renal and urinary disorders		Increased blood creatinine, increased blood urea	
General disorders and administration site conditions	Inflammation, pain	Thrombophlebitis, pain at the injection site	

Reporting of suspected adverse reactions

Dezzo Trading 392 (Pty) Ltd, 580034-5, MEROPENEM 500 SHANUR, MEROPENEM 1000 SHANUR, Powder for solution for injection or infusion, 500 mg & 1000 mg

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions to SAHPRA via the “**6.04 Adverse Drug Reaction Reporting Form**”, found online under SAHPRA’s publications: <https://www.sahpra.org.za/Publications/Index/8>

Suspected adverse reactions can also be reported directly to the HCR via medsafety@ustell.co.za

4.9 Overdose

Over-dosing could occur particularly in patients with renal impairment. Limited post-marketing experience indicates that if adverse events occur following over dosage, they are consistent with the adverse event profile described in section 4.9, are generally mild in severity and resolve on withdrawal or dose reduction.

Symptomatic treatment should be considered. In normal individuals rapid renal elimination will occur. Haemodialysis will remove MEROPENEM SHANUR and its metabolite.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Category and Class: A 20.1.1 Broad and medium spectrum antibiotics

Pharmacotherapeutic group: Antibacterials for systemic use, carbapenems

ATC Code: J01DH02

Meropenem is a carbapenem antibiotic for parenteral use, that is stable to human dehydropeptidase-I (DHP-I). It is structurally similar to imipenem.

Meropenem exerts its bactericidal action by interfering with vital bacterial cell wall synthesis.

Bactericidal concentrations are commonly the same as the minimum inhibitory concentrations (MICs).

Meropenem has a high degree of stability to almost all beta-lactamases produced by Gram-positive and Gram-negative bacteria. Meropenem is stable in susceptibility test systems.

Susceptibility tests can be performed using routine methods.

In vitro, meropenem can act synergistically with various antibiotics.

A post-antibiotic effect has been demonstrated in vitro and in vivo.

Meropenem may be active in vitro against imipenem-resistant strains of *Pseudomonas aeruginosa*.

Species for which acquired resistance may be a problem

Gram-positive anaerobes: *Enterococcus faecium*.

Dezzo Trading 392 (Pty) Ltd, 580034-5, MEROPENEM 500 SHANUR, MEROPENEM 1000 SHANUR, Powder for solution for injection or infusion, 500 mg & 1000 mg

Gram-negative aerobes: *Acinetobacter species*, *Burkholderia cepacia*, *Pseudomonas aeruginosa*.

Inherently resistant organisms

Gram-negative aerobes: *Stenotrophomonas maltophilia*, *Legionella species*.

Other micro-organisms: Chlamydophila pneumoniae, Chlamydophila psittaci, Coxiella burnetii, Mycoplasma pneumoniae.

All methicillin-resistant staphylococci are resistant to meropenem.

5.2 Pharmacokinetic properties

Absorption

After intravenous injection of MEROPENEM 500 SHANUR and MEROPENEM 1000 SHANUR over 5 minutes, peak plasma concentrations of about 50 and 112 microgram/mL respectively are attained.

The same doses infused over 30 minutes produce peak plasma concentrations of 23 and 49 microgram/mL, respectively.

Distribution

MEROPENEM SHANUR is widely distributed into body tissues and fluids including the cerebro-spinal fluid of patients with bacterial meningitis, achieving concentrations in excess of those required to inhibit most bacteria. It is about 2 % bound to plasma proteins.

Biotransformation

Approximately 70 % of a dose is recovered unchanged in the urine over a 12 hour period and urinary concentrations above 10 micrograms/mL are maintained for up to 5 hours at the 500 mg dose. No accumulation of meropenem in plasma or urine was observed with regimens using 500 mg administered every 8 hours or 1 g administered every 6 hours in volunteers with normal renal function. There is 1 metabolite, which is microbiologically inactive.

When multiple doses are administered at 8 hourly intervals to patients the concentrations at steady

state are approximately 20 % higher than after a single dose.

Elimination

MEROPENEM SHANUR has a plasma elimination half-life of about 1 hour in subjects with normal renal function.

Special populations

Renal impairment

In patients with renal insufficiency the plasma clearance of meropenem correlated with age-associated reduction in creatinine clearance.

Liver impairment

In patients with liver disease no effects of liver disease have been observed on the pharmacokinetics of meropenem.

Elderly

A reduction in plasma clearance, which correlated with age-associated reduction in creatinine clearance, was observed in the elderly.

No dose adjustment is required in the elderly patients, except in cases of moderate to severe renal impairment with creatinine clearance below 50 mL/minute.

Paediatric population

The pharmacokinetics of meropenem in children are essentially similar to those in adults. The elimination half-life for meropenem was approximately 1,5 hours in children under the age of 2 years.

The pharmacokinetics are linear over the dose range of 10 - 40 mg/kg.

5.3 Preclinical safety data

There was no evidence reproductive toxicity including teratogenic potential in studies in rats up to 750 mg/kg and in monkeys up to 360 mg/kg.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium carbonate

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

36 months

6.4 Special precautions for storage

Store at or below 30 °C.

For storage of the reconstituted solution(s) see section 6.6.

Diluent	Hours stable at 30 °C	Hours stable at 4 °C
0,9 % NaCl	8	48
5 % dextrose	2	8
10 % dextrose	2	4
5 % dextrose and 0,9 % sodium chloride	2	4
5 % dextrose and 0,2 % sodium chloride	2	8
5 % dextrose and 0,15% potassium chloride	2	12
5 % dextrose and 0,02 % sodium bicarbonate solution	2	12
5 % Dextrose in Normosol-M	2	16
5 % dextrose in Ringer's lactate	2	8
2,5 % dextrose and 0,45 % sodium chloride	6	24

2,5 % Mannitol	3	32
Ringer's	8	48
Ringer's lactate	8	24

Although chemical and physical in-use stability has been demonstrated as indicated in the table, from a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless reconstitution/dilution has taken place on controlled and validated aseptic conditions.

6.5 Nature and contents of container

MEROPENEM 500 SHANUR

The 20 mL vials are USP Type 1 glass (colourless), with a chlorobutyl rubber closure, flip-off aluminium seal with a polypropylene cap (blue colour). The vials are packed in a hard paper box, single or in packs of 10.

MEROPENEM 1000 SHANUR

The 20 mL vials are USP Type 1 glass (colourless), with a chlorobutyl rubber closure, flip-off aluminium seal with a polypropylene cap (red colour). The vials are packed in a hard paper box, single or in packs of 10.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Constitution, compatibility and stability:

Intravenous bolus injection administration

MEROPENEM SHANUR to be used for bolus intravenous injection should be constituted with sterile water for injection (10 mL/500 mg and 20 mL/1000 mg).

This provides an approximate available concentration of 50 mg/mL. Constituted solutions are clear or pale yellow.

Dose of Meropenem (50 mg/mL)	Amount of "Water for Injections" needed for dilution
500 mg	10 mL
1 g	20 mL

Intravenous infusion administration

For intravenous infusion MEROPENEM SHANUR vials may be directly constituted with 0,9 % sodium chloride or 5 % dextrose solutions for infusion.

MEROPENEM SHANUR infusion vials constituted with 0,9 % sodium chloride injection (2,5 mg/mL of meropenem concentration) were stable for up to 4 hours at 30 °C and for up to 36 hours at 4 °C.

Infusion vials constituted with 5 % dextrose injection (2,5 mg/mL of meropenem concentration) were stable for up to 2 hours at 30 °C and for up to 8 hours at 4 °C. Freshly prepared solutions of MEROPENEM SHANUR should be used whenever possible.

Dose of Meropenem (2,5 mg/mL)	Amount of "0,9 % sodium chloride or 5 % Dextrose" needed for dilution
500 mg	200 mL
1 g	400 mL

Infusion vials (500 mg and 1 g) may be directly constituted with a compatible infusion fluid. Alternatively, an injection vial may be constituted as above, then the resulting solution added to an I.V. container and further diluted with an appropriate infusion fluid (see table below). Solutions prepared for infusion (Meropenem concentrations ranging from 1 to 20 mg/mL, e.g. 500 mL/500 mg to 25 mL/500 mg or 1000 mL/1000 mg to 50 mL/1000 mg) may be stored in plastic intravenous bags at temperatures and with diluents as shown below:

MEROPENEM SHANUR should not be mixed with or physically added to solutions containing other medicines.

Diluent Infusions (1 – 20 mg/mL) prepared with:	Hours stable at 30 °C	Hours stable at 4 °C
0,9% NaCl	4	36
5 % dextrose	2	16
10 % dextrose	2	4
5 % dextrose and 0,9 % sodium chloride	2	4
5 % dextrose and 0,2 % sodium chloride	2	8
5 % dextrose and 0,15 % potassium chloride	2	12
5 % dextrose and 0,02 % sodium bicarbonate solution	2	12
5 % Dextrose in Normosol-M	2	16
5 % dextrose in Ringer's lactate	2	8
2,5 % dextrose and 0,45 % sodium chloride	6	24
2,5 % Mannitol	3	32
Ringer's	8	48
Ringer's lactate	8	24

Although chemical and physical in-use stability has been demonstrated as indicated in the table, from a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.

Solutions of MEROPENEM SHANUR should not be frozen.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Dezzo Trading 392 (Pty) Ltd

Dezzo Trading 392 (Pty) Ltd, 580034-5, MEROPENEM 500 SHANUR, MEROPENEM 1000 SHANUR,
Powder for solution for injection or infusion, 500 mg & 1000 mg

Loch House Unit 003

3A Eton Road, Parktown

Johannesburg, 2193

Tel: +27 87 405 9660

8. REGISTRATION NUMBERS

MEROPENEM 500 SHANUR: 58/20.1.1/0034

MEROPENEM 1000 SHANUR: 58/20.1.1/0035

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

03 September 2024

10. DATE OF REVISION OF THE TEXT